Klaria Pharma valued at SEK 812 million in commissioned report

Klaria Pharma Holding AB commissioned a valuation report from the firm Honeybadger, which estimates the company’s base scenario market value at SEK 812 million. The valuation accounts for a planned rights issue totaling approximately SEK 111.1 million, which is supported by subscription and guarantee commitments.

Following the rights issue, the share price is estimated at SEK 1.88. The valuation report notes that separate valuations were performed for the company's series TO1 warrants. The methodology primarily rests on projected future royalty income, a common valuation metric for pharmaceutical companies with pipeline assets.

While the report provides a baseline for the company's current financial position, it was prepared at the request of and paid for by Klaria Pharma. Investors often weigh commissioned valuations against independent market analysis and broader sector performance.